Evidence map›Paper›PMID 38725159›Full record

ArticleAging cell2024

Genetically determined blood pressure, antihypertensive drug classes, and frailty: A Mendelian randomization study.

Zhenhuang Zhuang, Yueying Li, Yimin Zhao, Ninghao Huang, Wenxiu Wang, Wendi Xiao, Jie Du, Xue Dong, Zimin Song, Jinzhu Jia and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Aging cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Zhenhuang ZhuangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Yueying LiDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Yimin ZhaoDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Ninghao HuangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Wenxiu WangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Wendi XiaoDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Jie DuNational Institute for Nutrition and Health, Chinese Center for Diseases Control and Prevention, Beijing, China.
Xue DongDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Zimin SongDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
Jinzhu JiaDepartment of Biostatistics, School of Public Health, Peking University, Beijing, China.
Zhonghua LiuDepartment of Biostatistics, Columbia University, New York, New York, USA.
Robert ClarkeClinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Lu QiDepartment of Epidemiology, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
Tao HuangDepartment of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.ORCID 0000-0002-0328-1368

Funding

National Natural Science Foundation of China 82173499
6 · The paper itself

Abstract

Observational studies have suggested that the use of antihypertensive drugs was associated with the risk of frailty; however, these findings may be biased by confounding and reverse causality. This study aimed to explore the effect of genetically predicted lifelong lowering blood pressure (BP) through different antihypertensive medications on frailty. One-sample Mendelian randomization (MR) and summary data-based MR (SMR) were applied. We utilized two kinds of genetic instruments to proxy the antihypertensive medications, including genetic variants within or nearby drugs target genes associated with systolic/diastolic BP, and expression level of the corresponding gene. Among 298,618 UK Biobank participants, one-sample MR analysis observed that genetically proxied BB use (relative risk ratios, 0.76; 95% CI, 0.65-0.90; p = 0.001) and CCB use (0.83; 0.72-0.95; p = 0.007), equivalent to a 10-mm Hg reduction in systolic BP, was significantly associated with lower risk of pre-frailty. In addition, although not statistically significant, the effect directions of systolic BP through ACEi variants (0.72; 0.39-1.33; p = 0.296) or thiazides variants (0.74; 0.53-1.03; p = 0.072) on pre-frailty were also protective. Similar results were obtained in analyses for diastolic BP. SMR of expression in artery showed that decreased expression level of KCNH2, a target gene of BBs, was associated with lower frailty index (beta -0.02, p = 2.87 × 10

Indexed as

Antihypertensive AgentsBlood PressureFrailtyMendelian Randomization AnalysisAgedFemaleHumansHypertensionMaleAntihypertensive Agentsantihypertensive medicationcausalityfrailtyMendelian randomization

Identifiers

PMID38725159
PMCPMC11258474

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.